Sublingual immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 3, 2001, Pages 441-444

  Frew, Anthony J ^a   Smith, Helen E ^b  

^a Department of Medical Specialties Southampton ^*  (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Efficacy; Immunotherapy; Rhinitis; Safety; Sublingual

Indexed keywords

ALLERGEN;

ALLERGIC RHINITIS; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG ANTIGENICITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; MAST CELL DEGRANULATION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; VALIDATION PROCESS;

EID: 0035094642     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.113525     Document Type: Article

References (49)

1. Allergen immunotherapy: Therapeutic vaccines for allergic disease
2. The oral administration of pollen
3. Oral pollen therapy in ragweed pollinosis
4. Is homeopathy a placebo response? Controlled trial of homeopathic potency with pollen in hay fever as a model
5. Low dose sublingual therapy in patients with allergic rhinitis and asthma due to house dust mite
6. Local immunotherapy
7. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen
8. Absorption of antigens after oral immunization and the simultaneous induction of specific systemic tolerance
9. Defence against allergic sensitisation in healthy lung: The role of inhalation tolerance
10. The regulation of immune responses to dietary proteins
11. Dendritic cells of the oral mucosa and the induction of oral tolerance
12. Dendritic cells produce IL-12 and direct the development of Th1 cells from naïve CD4+ T cells
13. The natural immune response to inhaled soluble protein antigens involves MHC class I-restricted CD8+ T-cell-mediated but MHC class II-restricted CD4+ T-cell-dependent immune deviation resulting in suppression of IgE production
14. Antigen presenting capacity of Langerhans cells from rat oral epithelium
15. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par J I) administered by non-injectable routes to healthy human beings
16. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mites. A double-blind study
17. A double-blind placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract
18. Double-blind placebo-controlled clinical trial of pre-seasonal immunotherapy with allergenic extracts of Olea europea pollen administered sublingually
19. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: A double-blind study
20. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy
21. Long term follow-up of nasal immunotherapy to Parietaria: Clinical and local immunological effects
22. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract
23. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double-blind study
24. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis
25. Immunotherapy with partially purified and standardized animal dander extracts. IV. Effects of 2 years of treatment
26. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs
27. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis
28. Double-blind trial of house dust mite immunotherapy in asthmatic children resident at high altitude
29. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: A dose titration study
30. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in reduced bronchial hyperreactivity
31. A 1 -year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults
32. Clinical efficacy of specific immunotherapy to cat dander: A double blind placebo controlled trial
33. House dust mite sublingual-swallow immunotherapy in perennial rhinitis: A double-blind placebo-controlled study
34. Sublingual immunotherapy
35. Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitised to mites: A double-blind, placebo-controlled study
36. Safety of sublingual-swallow immunotherapy in children and adults
37. Sublingual-swallow immunotherapy with a standardised five-grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis
38. Safety and efficacy of oral immunotherapy with standardized cat extract
39. Clinical efficacy of sublingual-swallow immunotherapy: A double-blind placebo-controlled trial of a standardised five-grass-pollen extract in rhinitis
40. Sublingual-swallow immunotherapy in patients with asthma due to house dust mites: A double-blind, placebo-controlled study
41. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation
42. Long-term efficacy of grass pollen immunotherapy
43. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children
44. Bee venom immunotherapy induces a shift in cytokine responses from a Th2 to a Th1 dominant pattern: Comparison of rush and conventional immunotherapy
45. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T-lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing mRNA for interferon-gamma
46. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Ph1l p1, a major grass pollen allergen
47. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardised olive pollen extract in paediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitisation
48. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
49. Sublingual immunotherapy: A double-blind, placebo-controlled trial with Parietaria judaica extract standardised in mass units in patients with rhinoconjunctivitis, asthma or both